Press Room

Article / Oct 11, 2007

Speech by Guy Villax at the VPP Star Presentation

East Windsor, New Jersey, 11 October 2007

Speech by Guy Villax on the occasion of the presentation of VPP Star plaque and flag

Mr. Ambassador [Mr. Joao Salgueiro, Ambassador of the Republic of Portugal to the UN]
Mr. Roskoski, [Mr. Gary Roskoski, Director- Marlton Area Office. OSHA] 
Mayor Mironov, [Ms. Janice Mironov, Mayor of the Township of East Windsor] 
Mr. Consul General [Mr. Francisco Azevedo, Consul General of Portugal in Newark]
Ladies and Gentlemen,
Dear Friends

I am very glad to be here with you.

I would like to thank the kind words from Mr. Gary Roskoski, Director and Mr. Martin Davies both of OSHA, from Mayor Mironov.

This is an important event for Hovione's Technology Transfer Center – we celebrate OSHA’s acceptance of our application to the VPP Star program.

This acknowledgement of an impeccable HSE record is something that I see as a reflection of the TTC’s standards, of the quality of the management of this site, and in a way this marks the coming of age of the TTC. Indeed this site is only 5 years old – and this is the first time that we have the chance to stop, invite our guests and friends and take a moment to look back. It’s not been easy, but we’ve clearly moved to the next step.

We have established the TTC as a member of an elite group – in the words of Edwin J. Foulke, Assistant Secretary of Labour – not just in HSE terms, but as a service provider of sophisticated R&D services to the pharma industry.

This is the correct moment to say a few words of thanks.

First to the East Windsor Township, its Mayor and Council – because they helped us decide to locate here, they welcomed us and told us “we’ll be as fast as you want provided you do it by the book!”.

Then to CUH2A, our architects that turned a dream, Dave, Bill and I had into reality – or at least into a blueprint – many sushi lunches at figuring out how to make it the best.

Turner and to Dion Hall of Eng Tech – for the hardware.

Millennium BCP bank – supported us all the way, and together with BES, BPI and CGD financed this investment.

The Consulate in Newark for endless stampings of endless papers.

The universities – Rider, Rutgers and Princeton – that lend us a hand only too often, train our young people so they will lead us in the future.

The Twin Rivers association – our neighbours… to whom we have tried very hard to be the opposite of a nuisance.

Certainly our customers – because at the end of the day they are the reason why we exist and succeed – I will pick a few names – Neurocrine Biosciences – because they gave us our first business here; and CVT and Astellas because they bet on us for an important new product.

I’d like to also thank all the Hovione people for their efforts and commitment in turning what back in 1999 and 2000 was but a dream – into a tangible reality that clients and competitors talk about, and journalists write about! Journalists have played an important role in our success - this is something we appreciate very much.

All Hovione sites perform over and above the regulations, and all get awards and commendations – they work hard to be a welcome part of their communities; they are often picked as an example to follow. So when I saw the letter from OSHA in Washington I was particularly pleased, because it came as a surprise – I did not even know the TTC had made the application – and it shows that whether they be in China or in America – Hovione people have the same culture, and look to meet the toughest challenges, to meet the highest standards – not because it is mandatory, but because this is just the way we work.

To achieve this means great team spirit, because Safety is everyone’s job – so cohesion and alignment are part of the whole process. This occasion is also a happy one because it marks an achievement, Diane and I are here, to share it with you – and to tell you how pleased we are to see after 50 years of hard work how we are able to get recognition for a job well done everywhere we go – and how this is the result of people that come from nearby, and from Macau, and from Portugal.

Going forward we have a great challenge – to continue to meet the standard. We all want to retain the VPP Star status – but to keep it requires effort and commitment – one day of lost work will cause us to loose the status… so we need to work hard because from where OSHA has put us, we can only go down… so I count on you.

Lastly I would like to give my congratulations to Dave that has led this project from its beginning and who should feel that all this is the achievement of a team he led, coached, pushed forward and got amazing results from. Congratulations to all of you for a great job well done – congratulations also to everyone else that worked here at the TTC, and may not be here to hear these words. Thank you – well done.

Guy Villax 
Chief Executive 
East Windsor, 11th October 2007

Also in the Press Room

See All

The CDMO is preparing for its New Jersey facility to become fully operational this year. Hovione’s multimillion-dollar investment in expanding its East Windsor, NJ manufacturing site is quickly coming to fruition. Contract Pharma will be visiting the site later in April 2026 to provide a unique overview of what’s new. As a preview, the Contract Pharma team met with Hovione at the Drug, Chemical & Associated Technologies Association (DCAT) Week. David Basile, Vice President of Technical Operations—Americas, spoke at the opening Member Company Announcement Forum on March 23, 2026. In this interview, Basile expands on his remarks at the Announcement Forum. As he explains, Hovione is concentrating not only on New Jersey, but also on facilities in Ireland and Portugal. Contract Pharma: Good manufacturing practice (GMP) operations will soon be fully operational at the New Jersey facility. How has Hovione progressed through this process since the initial investment cycle was announced last fall—or even prior? David Basile: It’s been a really great journey and evolution over the last two to three years, conceiving the plan to grow our U.S. footprint. It was one of the reasons I came aboard with Hovione, to grow that footprint and build our commercial manufacturing prowess in the States. In New Jersey, we had originated [the site] as a tech transfer center. [But] we wanted to grow the organization to be more equivalent with our Portugal and Ireland sites, to do more large-scale manufacturing. So, this is part of that journey. And that’s not just bricks-and-mortar and machinery. It’s been people, talent, partnerships with clients, supporting functions such as QC [quality control] and analytical development. We’re growing our R&D teams as well. It’s a comprehensive approach to systems, people, and processes. CP: At the Member Company Announcement Forum, you ran through some of the major technical specifications of the NJ expansion. Can you talk about a few of the highlights and their capabilities? Basile: This year we’ll be starting up two PSD-3 scale spray dryers. This is a useful scale of machinery for our clients. It plays nicely between the PSD-2 and PSD-4 scales that we have elsewhere in the network. I’d say it’s medium-to-large scale capacity; we could do 30 metric tons annually out of this type of a unit. Product to product, that differs, but we do have products that put that kind of volume out in a PSD-3, so it’s not small-scale. Customers want to hear this because [they want to gain] efficiency with their batch size, and turnaround time. And when we campaign, we can really see significant throughput with this line up of new machinery and assets. The first machine that we will start up is a Hastelloy unit, which is unique. We took a pause [in the construction timeline] to make that upgrade, as we had a client that needed this configuration. There are additional clients that are interested in it too, because you can do acidic solutions and more aggressive kinds of formulations as well as solvent-based formulations. So that’s a unique element of that first machine. The second machine is being qualified later this year. Kind of a twin, but this one is standard 316 stainless steel.  CP: When a company brings a new or expanded facility online, new personnel often accompanies the new tech. What is the workforce addition that you expect, and what are the challenges of retaining top talent? Basile: In preparation for commissioning and startup of this new equipment, we’ve already ramped our headcount up, to be ready for GMP launch. We’ve added roughly 20 employees in preparation for this first machine to go [live]. Over the next 18-plus months, we could see something on a similar scale, getting us up to that 40–50 headcount range for that facility once it’s fully operational—and more later on in 2028, when we bring in the CDC [continuous direct compression] Flex unit. That’s what’s really going to be transformative about this new facility: that integrated offering coming to life. CP: Even if the NJ facility is top of mind right now, let’s also touch on some of your plans in Europe. What is your vision for expanding in Europe in the next two to three years? Basile: Ideally, Hovione’s aim is to build an equivalent manufacturing network, where clients can go to any site across the globe and get a similar breadth and scale of offering. We’re doing that now in Ireland, expanding our PSD-4 scale spray drying. One unit was recently installed. Late last year, it went live. Then there’s at least one other new PSD-4 in motion, which is really exciting, because [spray dryers] at this site were historically [exclusive to] larger chemistry manufacturing for API [active pharmaceutical ingredient] synthesis. So now, they’re further building their muscle with additional large scale spray drying capacity. On the Portugal side, there’s a lot of great things going on. Our Tejo campus, in Seixal, Portugal, is a massive, 4.5-million-square-foot plot of land, and there’s a new, modular facility going up there. It’s incredibly exciting. The design of the facility has been well-thought through with material flows [and] gravity-fed processes. Here, we minimize handling and [maximize] speed of processing. It’s scalable. We call each one of these building segments a finger. You can copy and paste these fingers, and they are built to house both spray drying and drug product assets within each unit. So, why is that relevant? Because we can easily scale the number of fingers. When customers say, “we need more capacity,” we have the design on the table ready to go. We know how to execute, we know how to build and implement our technology platforms in a short timeframe. Deployment timeframes are truly becoming more and more relevant to our clients. CP: From last year’s DCAT Week to this year’s, what conversations are you having with industry colleagues about ever-changing geopolitics? Basile: We’re seeing that local, regional manufacturing capacity is vital. The concept of U.S. for U.S. and China for China seems to be a common theme that our clients are talking about. We happen to have an edge, as we [have already] started our journey of expanding our domestic U.S. capacity. So I think that’s a crucial piece to the puzzle, having dual-sided Atlantic manufacturing operations. The traditional global supply chain model is being challenged. Having soup-to-nuts sites that are fully autonomous in development, scale-up, tech transfer, all the way to commercial scale operation, is vital to Hovione, and how we’re protecting our supply chain. [Concerning] starting raw materials and Tier 2 suppliers, our procurement teams are out in the market making sure that there’s no single point of failure for critical materials [like] polymers and solvents that we utilize. We’re managing and mitigating risk by looking at those secondary suppliers across different geographies. CP: Encapsulating your planned expansions on both sides of the Atlantic, how would you sum up the value to the customer? Basile: It’s about speed-to-market. It’s one partner from early-phase development, clinical scale, all the way through commercial. They gain comfort, trust, and not just capacity and equipment time; it’s also about competency and depth of scientific expertise. We’re not just a traditional CDMO. There’s unique expertise in particle science and spray dried dispersions that we offer our clients that they don’t have. [With] traditional CDMOs, customers typically pay for time in [a particular] unit, for example, they’d say: “I need a machine, and I need [it for] three weeks.” Hovione is truly a partner to our clients. They’re leveraging our platforms, our know-how in spray drying, and our know-how in equipment design. Read the article at ContractPharma.com  

Article

Hovione Eyeing Manufacturing Expansion on Both Sides of Atlantic

Apr 06, 2026

With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can access its particle engineering expertise across multiple geographies.  That flexibility will be key for the Portugal-based company in the coming years as the pharmaceutical industry continues to embrace more regional supply chains. In a recent interview, Hovione's David Basile, VP of technical operations for the Americas, discussed this trend and the manufacturer's expansion project, which is set to come online in New Jersey next month.  In the coming weeks, Hovione plans to debut a new spray drying expansion at its campus in East Windsor, New Jersey. The company has invested $100 million to expand its campus, including new construction and the acquisition of an additional facility and greenfield land.  Specifically, one of two pharmaceutical spray drying-3 units, or PSD-3 units, will come online in the coming weeks to tackle amorphous active pharmaceutical ingredients (APIs) and amorphous solid dispersions, according to the company. With some 80% of new small molecules in development insoluble in water, Hovione’s particle engineering and amorphous solid dispersion platform helps medicine developers improve the solubility, bioavailability, and, in some cases, the stability of their drug candidates, Basile said.  The company boasts spray dryers from the lab scale to PSD3 at its original facility in East Windsor, in addition to the pair of large-scale machines about to be activated at the campus' new facility.  “We’re going for a single, unified site with capabilities across the campus to do drug substance through finished drug product under one governance and quality system,” - Basile told Fierce.   Read the full article at FiercePharma.com

Article

As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec

Mar 26, 2026